<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699465</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2007-006206-24</org_study_id>
    <nct_id>NCT00699465</nct_id>
  </id_info>
  <brief_title>Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage</brief_title>
  <official_title>A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the efficacy of using IPC during the acute phase of ICH in the prevention of
           VTE.

        -  To assess the safety and efficacy of additional therapy with enoxaparin.

        -  To compare the efficacy and safety of the European and American guideline
           recommendations.

        -  To provide an efficient and safe thromboprophylaxis for several weeks until the patient
           is able to walk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Although it has been poorly investigated, the risk of VTE among patients with acute
           primary intracerebral hemorrhage is generally believed to be at least as high as among
           patients with ischemic stroke.

        -  The currently available guidelines state that while low doses of subcutaneous heparin or
           low-molecular-weight heparin may reduce VTE, it is possible that their effect is
           counterbalanced by an increase in hemorrhagic complications.

        -  It is still unclear when (if ever) low-molecular-weight-heparin should be safely
           initiated in ICH patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cumulative occurrence of confirmed VTE, defined as the composite of symptomatic or asymptomatic DVT, or symptomatic or fatal PE occurring during the treatment period.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications including rebleedings occurring within the treatment period</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in ICH volume observed by head CT or at autopsy during the treatment period</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death occurring within the treatment period</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to any cause occurring within the treatment period</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Late enoxaparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Klexane</other_name>
    <other_name>Kendall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin placebo</intervention_name>
    <description>Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Klexane</other_name>
    <other_name>Kendall</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute primary ICH

          -  &gt; 17 years

          -  unable to walk

          -  admitted within 12 h after onset of ICH

          -  informed consent obtained

        Exclusion Criteria:

          -  other type of ICH than acute primary intracerebral hemorrhage

          -  patients who need neurosurgery

          -  evidence of VTE at screening

          -  thrombolytic treatment within the preceding week

          -  major surgery or major trauma within the preceding 3 months

          -  life expectancy less than 3 months due to comorbid disorders

          -  confirmed malignant disease (cancer)

          -  hepatitis and/or liver cirrhosis

          -  renal failure

          -  infectious disease (HIV, endocarditis etc.)

          -  current of previous hematologic disease

          -  recent active and untreated gastric/duodenal ulcer

          -  allergy or known hypersensitivity to enoxaparin or heparins

          -  known hypersensitivity to benzyl alcohol

          -  women of childbearing age if pregnant

          -  participation in another study within the preceding 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matti E Hillbom, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oulu University Central Hospital, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seppo S Juvela, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Turku University Central Hospital, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Turgut Tatlisumak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liisa K Luostarinen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Päijät-Häme Central Hospital, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aimo Rissanen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keski-Suomen Keskussairaala</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heikki Numminen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matti E Hillbom, MD, PhD</last_name>
    <phone>358-8-315-4518</phone>
    <email>matti.hillbom@oulu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juha T Huhtakangas, MD</last_name>
    <phone>358-8-315-4032</phone>
    <email>juha.huhtakangas@ppshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029 OYS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matti E Hillbom, professor</last_name>
      <phone>358-8-315-4518</phone>
      <email>matti.hillbom@oulu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Juha T Huhtakangas, MD</last_name>
      <phone>358-8-315-4032</phone>
      <email>juha.huhtakangas@ppshp.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Tarja H Haapaniemi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sami T Tetri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Bode, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pertti Saloheimo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eeva-Riitta Savolainen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22(4):294-316. Epub 2006 Jul 28. Erratum in: Cerebrovasc Dis. 2006;22(5-6):461. Katse, Markku [corrected to Kaste, Markku].</citation>
    <PMID>16926557</PMID>
  </reference>
  <reference>
    <citation>Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M; American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007 Jun;38(6):2001-23. Epub 2007 May 3.</citation>
    <PMID>17478736</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Oulu University Hospital (Matti Hillbom)</name_title>
    <organization>Oulu University Hospital</organization>
  </responsible_party>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Prevention of venous thromboembolism after ICH</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Intermittent pneumatic compression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

